Reports of the death of the patent dance have been slightly exaggerated

25 July 2017
biosimilars_samples_large

In a quarterly Special Report piece, Andrew Williams, patent law expert, partner at Chicago-based IP law firm McDonnell Boehnen Hulbert & Berghoff and chairman of its Patent Trial and Appeal Board (PTAB) Trials Practice Group, writes about a crucial case affecting the marketing of biosimilars in the USA.

Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) in 2010 in an effort to expedite the approval of generic biological drugs, known as biosimilars.

It took several years, however, for anyone to take advantage of the abbreviated approval pathway contained therein. This delay likely stemmed, at least in part, from the accompanying patent-resolution scheme.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars